Coronavirus: Oxford/AstraZeneca Phase 1/2 trial shows safe, immunogenic vaccine, S&P 500 positive

Yohay Elam FXStreet

The Lancet published the results of the University of Oxford's Phase 1/2 in a vaccine trial. The editor of the highly regarded medical publication has tweeted that the vaccine is safe, well-tolerated, and immunogenic.

The research is done in collaboration with AstraZeneca and the UK secured around 90 million doses of the candidate, ahead of a broader trial. Apart from creating antibodies, it also triggers the creation of T-cells. This development was previously described as "double-protection."

-- more to come

The phase 1/2 Oxford COVID-19 vaccine trial is now published. The vaccine is safe, well-tolerated, and immunogenic. Congratulations to Pedro Folegatti and colleagues. These results are extremely encouraging. https://t.co/oQp2eoZYIg
— richard horton (@richardhorton1) July 20, 2020

Administering the vaccine candidate triggered antibody responses in 32/35 (91%) participants after a single dose. After a booster dose, all participants had neutralizing activity.

The S&P 500 has turned positive after kicking off marginally lower at the beginning of a new trading week. Moderna and Pfizer/NioNTech.

Author

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

EUR/USD deflates to fresh lows, targets 1.1600

The selling pressure on EUR/USD now gathers extra pace, prompting the pair to hit fresh multi-week lows in the 1.1625-1.1620 band on Friday. The continuation of the downward bias comes in response to further gains in the US Dollar as market participants continue to assess the mixed release of US Nonfarm Payrolls in December.

GBP/USD breaks below 1.3400, challenges the 200-day SMA

GBP/USD remains under heavy fire and retreats for the fourth consecutive day on Friday. Indeed, Cable suffers the strong performance of the Greenback, intensified post-mixed NFP, and trades at shouting distance from its critical 200-day SMA near 1.3380.

Gold flirts with yearly tops around $4,500

Gold keeps its positive bias on Friday, adding to Thursday’s advance and challenging yearly highs in the $4,500 region per troy ounce. The risk-off sentiment favours the yellow metal despite the firmer tone in the Greenback and rising US Treasury yields.